Clinical Trial

A Bioequivalence Study of PP3M in Patients With Schizophrenia

Name: A Bioequivalence Study of PP3M in Patients With Schizophrenia — clinical trial record (NCT07493551)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting

View on ClinicalTrials.gov →

Summary

To evaluate the bioequivalence of the test formulation paliperidone palmitate injection (3M) produced by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and the reference formulation paliperidone palmitate injection (3M) (brand name: Invega Trinza) by Janssen Pharmaceutica N.V. under multiple-dose administration.

Trial Details

NCT Number	NCT07493551
Lead Sponsor	CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Conditions	Schizophrenia
Enrollment	260 participants
Start Date	2024-10-09
Primary Completion	2026-12-31 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-25